Neuroprotection And Neurodegenerative Diseases – A Review Article
Keywords:
Neurons, Beta blockers, Alzheimer’s disease, Natural products, neuroprotective,neurodegenerative disorder, Clinical trials.
Abstract
This paper will focus on neuroprotective effects of various drugs such as beta blockers and various natural products in the treatment of neurodegenerative disorder. We can define neuroprotection refers to recovery or regeneration of the nervous system, its cell, structure and function. Various neurodegenerative disorder such as Alzheimers disease which is characterized by progressive neuronal loss which can be treated with neuroprotective effects of beta blockers in a preclinical model of neurodegenerative disorder. Neuroprotective effects of various drugs are available only for limited indications. Development of new drugs require evaluation in animal studies, and human clinical trials. By the help of various natural products and suitable drug dosage neurodegenerative disorder can be improved. With few available treatments, Neurodegenerative illnesses are distinguished by a steady loss of neurons, as well as mental decline- present a serious threat to public health. Beta- blockers, commonly used to manage cardiovascular conditions, have been suggested to possess neuroprotective properties through their modulation of various cellular pathways implicated in neurodegeneration .While current treatment options primarily manage symptoms, the search for therapies that can slow or prevent disease progression remains a critical area of research. High blood pressure is treated with a class of medications known as beta blockers commonly administered, have emerged as potential candidates with neuroprotective properties.
References
1. Frank JE Vajda, Journal of clinical Neuroscience 9(1),4-8,2002, Neuroprotection and neurodegenerative disease.
2. Sonia Villapol, Juan M Saavedra, American journal of hypertension 28 (3),289-299,2015, Neuroprotective effects of angiotensin receptor blockers.
3. Petra Dunkel, Christina LL Chai,Beata Sperlagh,Paul B Huleatt, Peter Matyus, Expert opinion on investigational drugs 21(9), 1267-1308,2012, Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases.
4. Muhammad Zeeshan, Mohammad Hamidi, Terence Okeeffe,Esther H Bae, Kamil Hanna, Jornal of trauma and Acute care surgery 87 (5), 1140-1147,2019. Propranolol attenuates cognitive, learning and memory deficits in a murine model of traumatic brain injury.
5. Marta Dobarro, Lourdes Orejana, NorbertonAguirre, Maria Javier Ramirez, Neuropharmacology 64, 137-144,2013.Propranol restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model.
6. Rana E Kamal, Esther Menze, Amgad Albohy, Hebatalla I Ahmed, Samar S Azab, European Journal of Pharmacology 932, 175204,2022. Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico & in vivo anti-parkinson’s disease study.
7. Cristina Angeloni and David Vauzour, Natural products and Neuroprotection.
8. Udi Vazana, Ronel Veksler, Gaby S Pell, Ofer Prager, Michael Fassler, Yoash Chassidim, Journal pf Neuroscience 36(29),7727-7739,2016. Glutamate- mediated blood-brain barrier opening: implications for neuroprotection and drug delivery.
9. Andre Nieoullon, Journal of Applied Biomedicine 9 (4), 173-183, 2011. Neurodegenerative diseases and neuroprotection : current views and prospects.
10. Rebecca C. Brown, Alan H. Lockwood and Babasaheb R.Sonawane. Environmental Health perspectives volume 113, issue 9, pages 1250-1256. Neurodegenerative diseases: An overview of Environmental Risk Factors.
11. Alan I. Faden, MD, Bogdan stocia, MD, Arch Neurol. 2007,64 (6): 794-800. Neuroprotection challenges and opportunities.
12. William M Pardridge, Current opinion in investigational drugs 3 (12), 1753-1757,2002. Neurotrophins , neuroprotection and the blood-brain barrier.
13. Manon Leclerc, Stephanie Dudonne, Frederic Calon, International journal of molecular sciences 22 (7), 3356,2021.
14. Muneeb U Rehman, Adil F Wali, Anas Ahmad, Sheeba Shakeel, saiema Rasool, Raveesa Ali.Current neuropharmacology 17 (3), 247-267,2019. Neuroprotective strategies for neurological disorders by natural products.
15. Musthafa M Essa, Reshmi K Vijayan , Gloria Castellano-Gonzalez, Mustag A Memon. Nady. Neurochemical research 37, 1829-1842,2012. Neuroprotective effect of natural products against Alzheimers’s disease.
16. Rui FM Silva, Lea Pogacnik. Antioxidants 9 (1),61,2020. Polyphenols from food and natural products:Neuroprotection and safety.
17. Fei Fei, Ning Su, Xia Li, Zhou Fei, Neural Regeneration Research 15 (11), 2008-2015,2020. Neuroprotection mediated by natural products and their chemical derivatives.
18. Goutam Brahmachari,Elsevier 2017. Discovery and development of neuroprotective agents from natural products.
19. Xin Chen, Joshua Drew, Wren Berney and Wei Lei. Neuroprotective Natural products for Alzheimer’s disease.
20. Romij Uddin, Haeng Hoon Kim, Jai-Heon Lee, Sang Un Park. Neuroprotective effects of medicinal plants.
21. Lin X., Zhang N. Berberine: Pathways to protect neurons. Phytoether. Res. 2018;32 (8): 1501-1510 [Pubmed] [Google Scholar]
22. Fox S.H., Brotchie J.M. The MPTP- lesioned non- human primate models of Parkinson’s disease. Past, Present and future in Prog. Brain Res. Elsevier. 2010; 184: 133-157. [Pubmed] [Google Scholar]
23. Harvey A.L., Clark R.L., Mackay S.P., Johnston B.F Current strategies for drug discovery through natural products. Expert opin Drug Discov. 2010;5 (6) 559-568.
24. Kumar G.P., Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn. Rev. 2012; 6 (12); 81-90 . [PMID; 23055633]. [PMC free article] [Pubmed] [Google scholar]
25. Singh S., Dikshit M. Apoptotic neuronal death in Parkinson’s Disease: involvement of nitric oxide. Brain Res. Rev. 2007; 54 (2); 233-250. [Pubmed] [ Google Scholar].
26. Borda, M.J., Palamiuc L., & Hritcu, L. (2019). Evaluation of the neuroprotective effects of beta- adrenoceptor antagonists in an alzheimer’s disease model.
27. Alzheimer’s Association (2020). 2020 Alzheimer’s disease figures, Alzheimer’s & Dementia, 16 (3), 391-460.
28. Syrovatkina V, Alegre KO, Dey R,Haung XY. Regulation, signaling and physiological functions of G-proteins. J Mol Biol. 2016; 428 (19): 3850-3868.
29. Ryman W, Meier B. Transcriptional regulation in the Yeast GAL gene family; A complex genetic network. FASEB J, 2001; 15 (2); 281-286.
30. Strosberg AD. Structure, function, and regulation of adrenergic receptors. Protein Sci 1993; 2 (8); 1198-1209.
31. J.H. Choi et al. ‘Beta blocker use and risk of parkinson’s disease; a meta- analysis of cohort studies, “ European Journal of Neurology, vol.27, no. 8, pp. 1215-1222,2020.
32. H.J. Kim et al. “ Beta blocker use and risk of parkinson’s disease; a meta-analysis of cohort studies, “ European Journal of Neurology, vol. 27. No, 7, pp. 1075-1082, 2020.
33. M.S.LEE et al.., “ Beta-blocker use and risk of p;arkinson’s disease; a meta analysis of cohort studies, “European Journal of neurology, vol.27, no.5,pp- 775-782,2020.
34. D.Y. Kim J.Y Park and J.H Choi, “ Beta-blockers in the treatment of dementia; a systematic review and meta-analysis, “ BMC Geriatrics, vol.20, no, 1, p, 1, 2020.
35. M.A Quan et al., “ Cardiovascular diseases and the risk of dementia ; A case- control study’., Alzheimer’s & Dementia , vol.16. no. 12., pp. 1663-1671, 2020.
36. J.Sun et al., “ Beta- blockers and risk of dementia; a systematic review and meta- analysis, Neuroepidemiology, vol,54,no.3 , pp. 171-180, 2020.
37. S.Kim et al., “ Effect of beta blockers on cognitive function and dementia risk; A systematic review and meta- analysis, “ Neurology, vol.94, no,14, pp e1523-e1533,2020.
38. A. Ahn et al., “ The protective effect of beta-blockers on neurodegenerative diseases; a systematic review and meta-analysis.
39. S.park et al., “ Beta-blocker use and risk of parkinson’s disease ; a meta-analysis, “ European Journal of Neurology, vol.27,no.1,pp. 93-100,2020.
40. M.A. Quan et al., “ Cardiovascular diseases and the risk of dementia; A case-control study.” Alzheimer’s & Dementia, vol.16,no. 12,pp. 1663-1671.
41. A.S. Mushtaq et al, “The potential role of beta-blockers in the treatment of neurodegenerative diseases, CNS Drugs, vol.34, no., 8.pp. 799-816,2020.
42. Reil JC,Hohl M, Selejan S,Lipp P, Drautz F, Muller P. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33 (16); 2098-2108.
43. Pedersen Me, Cockcroft JR. The vasodilatory beta- blockers. Expert opin Investig Drugs. 2005; 14 (5); 557-573.
44. Ferreira R, Santos T, Amaral R, et al. Neuropeptide Y inhibits interleukin-1beta-induced phagocytosis by microglial cells. J Neuroinflammation, 2011;8;169.
45. Martini SR,Kent JA. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors . South Med J.1998;91 (10); 933-937.
46. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick,R., Mork, S., & Bo,L (1998). Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine, 338(5), 278-285.
47. Pitt, D., Werner, P., & Raine , C.S (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine, 6(1). 67-70.
48. Lassmann, H., Bruck, W., & LUCCHINETTI., C. (2007). The immunopathology of multiple sclerosis. An overview. Brain Pathology,17 (2), 210-218.
49. Compston, A., & Coles, A. (2008). Multiple sclerosis. The lancet, 372 (9648), 1502-1517.
50. Hardy, J., & Selkoe,D. J (2002).The amyloid hypothesis of Alzheimer’s disease; progress and problems on the road to therapeutics. Science, 297 (5580), 353-356.
51. Alzheimer’s association. (2020). 2020 Alzheimers’s disease facts and figures. Alzheimer’s & dementia, 16 (3), 391-460.
52. Ballard, C., Gauthier. S., Corbett., A., Brayne, C., Aarsland, D & Jones , E (2011). Alzheimer’s disease. The Lancet, 377 (9770), 1019-1031.
53. Giacobini E, GOLD G. Alzheimer disease therapy- moving from amyloid beta to tau.Nat Rev Neurol. W2013;9(12): 677-686.
54. Mrak RE, Griffin WS. Gila and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005; 26(3): 349-354.
55. Zhao L, Chen S, Sherchan P, et al. Recombinant C1 inhibitor in clinical trials for treatment of neurological disorders. Front Immunol. 2018;9:2361.
56. Amann LC,Gandal MJ, Halene TB,et al. Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull. 2010;83(3-4): 147-161.
57. Reas ET, Laughlin GA,Bergstrom J,et al. Beta-blockers are associated with cognitive impairment in elderly patients. Alzheimer Dis Assoc Disord. 2019;33(1): 71-76.
58. Vatner DE, Vatner SF. Neprilysin inhibition produces dual inhibition of the cardiac sympathetic and renin angiotensin system. Curr Hypertens Rep. 2015; 17 (3); 19.
59. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014; 114(6): 1004-1021.
60. Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114(11): 1815-1826.
2. Sonia Villapol, Juan M Saavedra, American journal of hypertension 28 (3),289-299,2015, Neuroprotective effects of angiotensin receptor blockers.
3. Petra Dunkel, Christina LL Chai,Beata Sperlagh,Paul B Huleatt, Peter Matyus, Expert opinion on investigational drugs 21(9), 1267-1308,2012, Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases.
4. Muhammad Zeeshan, Mohammad Hamidi, Terence Okeeffe,Esther H Bae, Kamil Hanna, Jornal of trauma and Acute care surgery 87 (5), 1140-1147,2019. Propranolol attenuates cognitive, learning and memory deficits in a murine model of traumatic brain injury.
5. Marta Dobarro, Lourdes Orejana, NorbertonAguirre, Maria Javier Ramirez, Neuropharmacology 64, 137-144,2013.Propranol restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model.
6. Rana E Kamal, Esther Menze, Amgad Albohy, Hebatalla I Ahmed, Samar S Azab, European Journal of Pharmacology 932, 175204,2022. Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico & in vivo anti-parkinson’s disease study.
7. Cristina Angeloni and David Vauzour, Natural products and Neuroprotection.
8. Udi Vazana, Ronel Veksler, Gaby S Pell, Ofer Prager, Michael Fassler, Yoash Chassidim, Journal pf Neuroscience 36(29),7727-7739,2016. Glutamate- mediated blood-brain barrier opening: implications for neuroprotection and drug delivery.
9. Andre Nieoullon, Journal of Applied Biomedicine 9 (4), 173-183, 2011. Neurodegenerative diseases and neuroprotection : current views and prospects.
10. Rebecca C. Brown, Alan H. Lockwood and Babasaheb R.Sonawane. Environmental Health perspectives volume 113, issue 9, pages 1250-1256. Neurodegenerative diseases: An overview of Environmental Risk Factors.
11. Alan I. Faden, MD, Bogdan stocia, MD, Arch Neurol. 2007,64 (6): 794-800. Neuroprotection challenges and opportunities.
12. William M Pardridge, Current opinion in investigational drugs 3 (12), 1753-1757,2002. Neurotrophins , neuroprotection and the blood-brain barrier.
13. Manon Leclerc, Stephanie Dudonne, Frederic Calon, International journal of molecular sciences 22 (7), 3356,2021.
14. Muneeb U Rehman, Adil F Wali, Anas Ahmad, Sheeba Shakeel, saiema Rasool, Raveesa Ali.Current neuropharmacology 17 (3), 247-267,2019. Neuroprotective strategies for neurological disorders by natural products.
15. Musthafa M Essa, Reshmi K Vijayan , Gloria Castellano-Gonzalez, Mustag A Memon. Nady. Neurochemical research 37, 1829-1842,2012. Neuroprotective effect of natural products against Alzheimers’s disease.
16. Rui FM Silva, Lea Pogacnik. Antioxidants 9 (1),61,2020. Polyphenols from food and natural products:Neuroprotection and safety.
17. Fei Fei, Ning Su, Xia Li, Zhou Fei, Neural Regeneration Research 15 (11), 2008-2015,2020. Neuroprotection mediated by natural products and their chemical derivatives.
18. Goutam Brahmachari,Elsevier 2017. Discovery and development of neuroprotective agents from natural products.
19. Xin Chen, Joshua Drew, Wren Berney and Wei Lei. Neuroprotective Natural products for Alzheimer’s disease.
20. Romij Uddin, Haeng Hoon Kim, Jai-Heon Lee, Sang Un Park. Neuroprotective effects of medicinal plants.
21. Lin X., Zhang N. Berberine: Pathways to protect neurons. Phytoether. Res. 2018;32 (8): 1501-1510 [Pubmed] [Google Scholar]
22. Fox S.H., Brotchie J.M. The MPTP- lesioned non- human primate models of Parkinson’s disease. Past, Present and future in Prog. Brain Res. Elsevier. 2010; 184: 133-157. [Pubmed] [Google Scholar]
23. Harvey A.L., Clark R.L., Mackay S.P., Johnston B.F Current strategies for drug discovery through natural products. Expert opin Drug Discov. 2010;5 (6) 559-568.
24. Kumar G.P., Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn. Rev. 2012; 6 (12); 81-90 . [PMID; 23055633]. [PMC free article] [Pubmed] [Google scholar]
25. Singh S., Dikshit M. Apoptotic neuronal death in Parkinson’s Disease: involvement of nitric oxide. Brain Res. Rev. 2007; 54 (2); 233-250. [Pubmed] [ Google Scholar].
26. Borda, M.J., Palamiuc L., & Hritcu, L. (2019). Evaluation of the neuroprotective effects of beta- adrenoceptor antagonists in an alzheimer’s disease model.
27. Alzheimer’s Association (2020). 2020 Alzheimer’s disease figures, Alzheimer’s & Dementia, 16 (3), 391-460.
28. Syrovatkina V, Alegre KO, Dey R,Haung XY. Regulation, signaling and physiological functions of G-proteins. J Mol Biol. 2016; 428 (19): 3850-3868.
29. Ryman W, Meier B. Transcriptional regulation in the Yeast GAL gene family; A complex genetic network. FASEB J, 2001; 15 (2); 281-286.
30. Strosberg AD. Structure, function, and regulation of adrenergic receptors. Protein Sci 1993; 2 (8); 1198-1209.
31. J.H. Choi et al. ‘Beta blocker use and risk of parkinson’s disease; a meta- analysis of cohort studies, “ European Journal of Neurology, vol.27, no. 8, pp. 1215-1222,2020.
32. H.J. Kim et al. “ Beta blocker use and risk of parkinson’s disease; a meta-analysis of cohort studies, “ European Journal of Neurology, vol. 27. No, 7, pp. 1075-1082, 2020.
33. M.S.LEE et al.., “ Beta-blocker use and risk of p;arkinson’s disease; a meta analysis of cohort studies, “European Journal of neurology, vol.27, no.5,pp- 775-782,2020.
34. D.Y. Kim J.Y Park and J.H Choi, “ Beta-blockers in the treatment of dementia; a systematic review and meta-analysis, “ BMC Geriatrics, vol.20, no, 1, p, 1, 2020.
35. M.A Quan et al., “ Cardiovascular diseases and the risk of dementia ; A case- control study’., Alzheimer’s & Dementia , vol.16. no. 12., pp. 1663-1671, 2020.
36. J.Sun et al., “ Beta- blockers and risk of dementia; a systematic review and meta- analysis, Neuroepidemiology, vol,54,no.3 , pp. 171-180, 2020.
37. S.Kim et al., “ Effect of beta blockers on cognitive function and dementia risk; A systematic review and meta- analysis, “ Neurology, vol.94, no,14, pp e1523-e1533,2020.
38. A. Ahn et al., “ The protective effect of beta-blockers on neurodegenerative diseases; a systematic review and meta-analysis.
39. S.park et al., “ Beta-blocker use and risk of parkinson’s disease ; a meta-analysis, “ European Journal of Neurology, vol.27,no.1,pp. 93-100,2020.
40. M.A. Quan et al., “ Cardiovascular diseases and the risk of dementia; A case-control study.” Alzheimer’s & Dementia, vol.16,no. 12,pp. 1663-1671.
41. A.S. Mushtaq et al, “The potential role of beta-blockers in the treatment of neurodegenerative diseases, CNS Drugs, vol.34, no., 8.pp. 799-816,2020.
42. Reil JC,Hohl M, Selejan S,Lipp P, Drautz F, Muller P. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33 (16); 2098-2108.
43. Pedersen Me, Cockcroft JR. The vasodilatory beta- blockers. Expert opin Investig Drugs. 2005; 14 (5); 557-573.
44. Ferreira R, Santos T, Amaral R, et al. Neuropeptide Y inhibits interleukin-1beta-induced phagocytosis by microglial cells. J Neuroinflammation, 2011;8;169.
45. Martini SR,Kent JA. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors . South Med J.1998;91 (10); 933-937.
46. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick,R., Mork, S., & Bo,L (1998). Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine, 338(5), 278-285.
47. Pitt, D., Werner, P., & Raine , C.S (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine, 6(1). 67-70.
48. Lassmann, H., Bruck, W., & LUCCHINETTI., C. (2007). The immunopathology of multiple sclerosis. An overview. Brain Pathology,17 (2), 210-218.
49. Compston, A., & Coles, A. (2008). Multiple sclerosis. The lancet, 372 (9648), 1502-1517.
50. Hardy, J., & Selkoe,D. J (2002).The amyloid hypothesis of Alzheimer’s disease; progress and problems on the road to therapeutics. Science, 297 (5580), 353-356.
51. Alzheimer’s association. (2020). 2020 Alzheimers’s disease facts and figures. Alzheimer’s & dementia, 16 (3), 391-460.
52. Ballard, C., Gauthier. S., Corbett., A., Brayne, C., Aarsland, D & Jones , E (2011). Alzheimer’s disease. The Lancet, 377 (9770), 1019-1031.
53. Giacobini E, GOLD G. Alzheimer disease therapy- moving from amyloid beta to tau.Nat Rev Neurol. W2013;9(12): 677-686.
54. Mrak RE, Griffin WS. Gila and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005; 26(3): 349-354.
55. Zhao L, Chen S, Sherchan P, et al. Recombinant C1 inhibitor in clinical trials for treatment of neurological disorders. Front Immunol. 2018;9:2361.
56. Amann LC,Gandal MJ, Halene TB,et al. Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull. 2010;83(3-4): 147-161.
57. Reas ET, Laughlin GA,Bergstrom J,et al. Beta-blockers are associated with cognitive impairment in elderly patients. Alzheimer Dis Assoc Disord. 2019;33(1): 71-76.
58. Vatner DE, Vatner SF. Neprilysin inhibition produces dual inhibition of the cardiac sympathetic and renin angiotensin system. Curr Hypertens Rep. 2015; 17 (3); 19.
59. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014; 114(6): 1004-1021.
60. Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114(11): 1815-1826.
Published
2024-01-20
How to Cite
Dr. Praveen Kumar, Dr. Vishwadeepak kimothi, Miss Sushila rawat, & Sneha kumari. (2024). Neuroprotection And Neurodegenerative Diseases – A Review Article. Revista Electronica De Veterinaria, 25(1), 890-895. https://doi.org/10.69980/redvet.v25i1.739
Issue
Section
Articles
